77 results on '"Olbrich D"'
Search Results
2. Precision radiotherapy for metastatic spinal cord compression: Final results of the PRE-MODE Trial
- Author
-
Rades D, Cacicedo J, Conde-Moreno AJ, Segedin B, But-Hadzic J, Groselj B, Kevlishvili G, Lomidze D, Jurio RC, Rubio C, Perez-Romasanta LA, Alvarez-Gracia A, Olbrich D, Doemer C, Schild SE, and Hollaender NH
- Subjects
historical control group, local progression-free survival, metastatic spinal cord compression, phase 2 trial, precision radiotherapy - Abstract
To investigate precision radiotherapy for metastatic spinal cord compression (MSCC) and compare it to conventional radiotherapy.
- Published
- 2020
3. Patient Reported Experience with Treatment Modalities and Safety of Adjuvant Breast Radiotherapy - First Results of the Randomized HYPOSIB – Study
- Author
-
Dunst, J., primary, Krug, D., additional, Schreiber, A., additional, Boicev, A.D., additional, Zimmer, J., additional, Laubach, R., additional, Weidner, N., additional, Dinges, S.E., additional, Hipp, M., additional, Schneider, R., additional, Weinstrauch, E., additional, Martin, T., additional, Hörner-Rieber, J., additional, Vonthein, R., additional, Olbrich, D., additional, Illen, A., additional, Koenig, I., additional, and Dellas, K., additional
- Published
- 2020
- Full Text
- View/download PDF
4. Unerwünschte Ereignisse und Hautreaktionen in der HYPOSIB - Studie (ARO 2013-05): Daten des Sicherheitsbericht 2019
- Author
-
Krug, D, additional, van Mackelenbergh, MT, additional, Heilmann, T, additional, Elessawy, M, additional, Schreiber, A, additional, Zimmer, J, additional, Boicev, AD, additional, Laubach, R, additional, Weidner, N, additional, Dinges, S, additional, Hipp, M, additional, Weinstrauch, E, additional, Schneider, R, additional, Martin, T, additional, Vonthein, R, additional, Olbrich, D, additional, Illen, A, additional, König, IR, additional, Dellas, K, additional, Rody, A, additional, Maass, N, additional, and Dunst, J, additional
- Published
- 2020
- Full Text
- View/download PDF
5. Wie empfinden und bewerten Patientinnen mit Mammakarzinom die einzelnen Therapiemodalitäten: Ergebnisse einer Patientenbefragung im Rahmen der HYPOSIB - Studie (ARO 2013-05)
- Author
-
Krug, D, additional, van Mackelenbergh, MT, additional, Heilmann, T, additional, Elessawy, M, additional, Schreiber, A, additional, Zimmer, J, additional, Boicev, AD, additional, Laubach, R, additional, Weidner, N, additional, Dinges, S, additional, Hipp, M, additional, Weinstrauch, E, additional, Schneider, R, additional, Martin, T, additional, Vonthein, R, additional, Olbrich, D, additional, Illen, A, additional, König, IR, additional, Dellas, K, additional, Rody, A, additional, Maass, N, additional, and Dunst, J, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Wirksamkeit von Disease-Management-Programmen für Asthma und COPD? Ergebnisse einer Querschnittstudie
- Author
-
Kanniess, F., additional, Krockenberger, K., additional, Oepen, P., additional, Hedrich, R., additional, Olbrich, D., additional, Hessler, N., additional, Ziegler, A., additional, and Langer-Brauburger, B., additional
- Published
- 2020
- Full Text
- View/download PDF
7. Fraktionierung und Prognosefaktoren in der HYPOSIB-Studie – Hypofraktionierung mit simultan-integriertem Boost versus Standard-Fraktionierung beim Mammakarzinom
- Author
-
Krug, D, additional, Olbrich, D, additional, Vonthein, R, additional, Illen, A, additional, König, IR, additional, Dellas, K, additional, and Dunst, J, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Lokale Strahlentherapie von Metastasen beim oligometastasierten Mammakarzinom – die OLIGOMA-Studie der ARO
- Author
-
Krug, D, additional, Vonthein, R, additional, Olbrich, D, additional, Illen, A, additional, König, IR, additional, Dellas, K, additional, and Dunst, J, additional
- Published
- 2019
- Full Text
- View/download PDF
9. High-precision radiotherapy of motor deficits due to metastatic spinal cord compression (PRE-MODE): a multicenter phase 2 study
- Author
-
Rades D, Cacicedo J, Conde-Moreno AJ, Doemer C, Dunst J, Lomidze D, Segedin B, Olbrich D, and Holländer NH
- Subjects
Quality of life ,Stereotactic body radiotherapy ,Volumetric modulated arc therapy ,Pain ,Metastatic spinal cord compression ,Overall survival ,Local progression-free survival ,Motor function - Abstract
Background: For metastatic spinal cord compression (MSCC), conventional radiotherapy with 10 x 3 Gy in 2 weeks results in better local progression-free survival (LPFS) than 5 x 4 Gy in 1 week. Since patients with MSCC are often significantly impaired, an overall treatment time of 1 week would be preferable if resulting in similar outcomes as longer programs. This may be achieved with 5 x 5 Gy in 1 week, since the biologically effective dose is similar to 10 x 3 Gy. It can be expected that 5 x 5 Gy (like 10 x 3) Gy results in better LPFS than 5 x 4 Gy in 1 week. Methods/Design: This phase 2 study investigates LPFS after high-precision RT with 5 x 5 Gy in 1 week. LPFS is defined as freedom from both progression of motor deficits during RT and new or progressive motor deficits dur to an in-field recurrence of MSCC following RT. Considering the tolerance dose of the spinal cord, 5 x 5 Gy can be safely administered with high-precision radiotherapy such as volumetric modulated arc therapy (MAT) or stereotactic body radiotherapy (SBRT). Maximum dose to the spinal cord should not exceed 101.5% of the prescribed dose to keep the risk of radiation myelopathy below 0.03%. Primary endpoint is LPFS at 6 months following radiotherapy; secondary endpoints include motor function/ability to walk, sensory function, sphincter dysfunction, LPFS directly and 1 and 3 months following radiotherapy, overall survival, pain relief, quality of life and toxicity. Follow-up visits will be performed directly and at 1, 3 and 6 months following radiotherapy. After completion of this phase 2 study, patients will be compared to a historical control group receiving conventional radiotherapy with 5 x 4 Gy in 1 week. Forty-four patients will be included assuming 5 x 5 Gy will provide the same benefit in LPFS when compared to 5 x 4 Gy as reported for 10 x 3 Gy. Discussion: If superiority regarding LPFS is shown for high-precision radiotherapy with 5 x 5 Gy when compared to conventional radiotherapy with 5 x 4 Gy, patients with MSCC would benefit from 5 x 5 Gy, since high LPFS rates could be achieved with 1 week of radiotherapy instead of 2 weeks (10 x 3 Gy).
- Published
- 2017
10. Host and Habitat Use by Parasitoids (Hymenoptera: Pteromalidae) of House Fly and Stable Fly (Diptera: Muscidae) Pupae
- Author
-
Olbrich, D. L, primary and King, B. H, additional
- Published
- 2018
- Full Text
- View/download PDF
11. An omics-based strategy using coenzyme Q10 in patients with Parkinson's disease: Design of a concept evaluation in a double-blind randomised placebo-controlled phase II study
- Author
-
Heßler, N, Kasten, M, Berg, D, Brüggemann, N, Gasser, T, Krockenberger, K, Olbrich, D, Prasuhn, J, Klein, C, Ziegler, A, Heßler, N, Kasten, M, Berg, D, Brüggemann, N, Gasser, T, Krockenberger, K, Olbrich, D, Prasuhn, J, Klein, C, and Ziegler, A
- Published
- 2017
12. Psychogene Komorbidität bei chronischen Rückenschmerzpatienten – Screeningverfahren am Beispiel der Symptom-Checkliste SCL-90-R
- Author
-
Sörries, S and Olbrich, D
- Published
- 2024
- Full Text
- View/download PDF
13. HYPOSIB – Hypofraktionierung mit simultan-integriertem Boost versus Standard-Fraktionierung beim Mammakarzinom: Die größte randomisierte, kontrollierte Strahlentherapie-Studie Deutschlands – Ein Zwischenstand
- Author
-
Zimmer, J, primary, Krockenberger, K, additional, Loley, C, additional, Olbrich, D, additional, Dellas, K, additional, Ziegler, A, additional, and Dunst, J, additional
- Published
- 2016
- Full Text
- View/download PDF
14. Beschäftigungsfähigkeit teilhabeorientiert sichern (Betsi): Ergebnisse der Einjahreskatamnese von Präventionsmaßnahmen der Deutschen Rentenversicherung
- Author
-
Kittel, J., additional, Fröhlich, S., additional, Heilmeyer, P., additional, Olbrich, D., additional, Karoff, M., additional, and Greitemann, B., additional
- Published
- 2014
- Full Text
- View/download PDF
15. Thermische Ablation pimärer Lungenmalignome
- Author
-
Helmberger, T, primary, Schneider, P, additional, and Olbrich, D, additional
- Published
- 2013
- Full Text
- View/download PDF
16. Lokoregionäre Therapie des CC - was geht, was nicht?
- Author
-
Helmberger, T, primary, Schneider, P, additional, and Olbrich, D, additional
- Published
- 2013
- Full Text
- View/download PDF
17. Psychogene Komorbidität bei chronischen Rückenschmerzpatienten - Screeningverfahren am Beispiel der Symptom-Checkliste SCL-90-R
- Author
-
Sörries, S, Olbrich, D, Sörries, S, and Olbrich, D
- Published
- 2003
18. Psychogene Komorbidität bei chronischen Rückenschmerzpatienten – Screeningverfahren am Beispiel der Symptom-Checkliste SCL-90-R
- Author
-
Sörries, S, primary and Olbrich, D, additional
- Published
- 2003
- Full Text
- View/download PDF
19. Beschäftigungsfähigkeit teilhabeorientiert sichern (Betsi): Ergebnisse der Einjahreskatamnese von Präventionsmaßnahmen der Deutschen Rentenversicherung.
- Author
-
Kittel, J., Fröhlich, S. M., Heilmeyer, P., Olbrich, D., Karoff, M., and Greitemann, B.
- Published
- 2014
- Full Text
- View/download PDF
20. Mehrschicht- Computertomographie des Dünndarms
- Author
-
Rust, G.-F., primary, Holzknecht, N., additional, Olbrich, D., additional, Schöpf, U., additional, Brüning, R., additional, and Reiser, M., additional
- Published
- 1999
- Full Text
- View/download PDF
21. Psychiatrische Hospitalisierung bei Geschiedenen.
- Author
-
Olbrich, D. and Bojanovsky, J.
- Published
- 1981
- Full Text
- View/download PDF
22. Development, Involvement and Use of an Overarching In-House Registry for Clinical Trials.
- Author
-
Ablaß T, Simon F, Schwitlick C, Olbrich D, Brandt K, Hohensee I, von Bubnoff N, Baldus C, Ingenerf J, Schreiweis B, and Kock-Schoppenhauer AK
- Subjects
- Humans, United Kingdom, Registries, Clinical Trials as Topic
- Abstract
Introduction: Conducting clinical studies is an integral part of the clinical research repertoire of university hospitals. A wealth of organizational competences must always be available in a central location and in an up-to-date form for appropriate administration. Information such as the number of ongoing studies, and the number of enrolled participants is required for tasks related to e.g. sponsor quality management and KPIs. A registry for clinical trials can answer these questions and enhance the exchange of information., Methods: Requirements for an in-house registry for clinical trials were defined in a multidisciplinary task force. The requirements included interfaces and key abilities to create customized reports to fulfill the obligation to provide evidence., Results: The study registry is productive since May 2020 and internal interfaces have been implemented to ensure consistency between systems and the documented studies. Manually recorded data is enhanced by interfaces to primary registers. The comprehensive data set in the study register enables the creation of individual queries at any time for a variety of questions., Discussion: The UKSH study register has already demonstrated its usefulness in various applications and several projects. The extensive data set and the modular realization allows many current and future requirements to be met.
- Published
- 2024
- Full Text
- View/download PDF
23. Coronary Angiography After Out-of-Hospital Cardiac Arrest Without ST-Segment Elevation: One-Year Outcomes of a Randomized Clinical Trial.
- Author
-
Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, Skurk C, Landmesser U, Graf T, Eitel I, Fuernau G, Haake H, Nordbeck P, Hammer F, Felix SB, Hassager C, Kjærgaard J, Fichtlscherer S, Ledwoch J, Lenk K, Joner M, Steiner S, Liebetrau C, Voigt I, Zeymer U, Brand M, Schmitz R, Horstkotte J, Jacobshagen C, Pöss J, Abdel-Wahab M, Lurz P, Jobs A, de Waha S, Olbrich D, Sandig F, König IR, Brett S, Vens M, Klinge K, and Thiele H
- Subjects
- Humans, Male, Middle Aged, Aged, Female, Coronary Angiography adverse effects, Hospitalization, Out-of-Hospital Cardiac Arrest diagnostic imaging, Out-of-Hospital Cardiac Arrest therapy, Myocardial Infarction complications, Heart Failure complications
- Abstract
Importance: Myocardial infarction is a frequent cause of out-of-hospital cardiac arrest (OHCA). The long-term effect of early coronary angiography on patients with OHCA with possible coronary trigger but no ST-segment elevation remains unclear., Objective: To compare the clinical outcomes of early unselective angiography with the clinical outcomes of a delayed or selective approach for successfully resuscitated patients with OHCA of presumed cardiac origin without ST-segment elevation at 1-year follow-up., Design, Setting, and Participants: The TOMAHAWK trial was a multicenter, international (Germany and Denmark), investigator-initiated, open-label, randomized clinical trial enrolling 554 patients between November 23, 2016, to September 20, 2019. Patients with stable return of spontaneous circulation after OHCA of presumed cardiac origin but without ST-segment elevation on the postresuscitation electrocardiogram were eligible for inclusion. A total of 554 patients were randomized to either immediate coronary angiography after hospital admission or an initial intensive care assessment with delayed or selective angiography after a minimum of 24 hours. All 554 patients were included in survival analyses during the follow-up period of 1 year. Secondary clinical outcomes were assessed only for participants alive at 1 year to account for the competing risk of death., Interventions: Early vs delayed or selective coronary angiography and revascularization if indicated., Main Outcomes and Measures: Evaluations in this secondary analysis included all-cause mortality after 1 year, as well as severe neurologic deficit, myocardial infarction, and rehospitalization for congestive heart failure in survivors at 1 year., Results: A total of 281 patients were randomized to the immediate angiography group and 273 to the delayed or selective group, with a median age of 70 years (IQR, 60-78 years). A total of 369 of 530 patients (69.6%) were male, and 268 of 483 patients (55.5%) had a shockable arrest rhythm. At 1 year, all-cause mortality was 60.8% (161 of 265) in the immediate angiography group and 54.3% (144 of 265) in the delayed or selective angiography group without significant difference between the treatment strategies, trending toward an increase in mortality with immediate angiography (hazard ratio, 1.25; 95% CI, 0.99-1.57; P = .05). For patients surviving until 1 year, the rates of severe neurologic deficit, myocardial infarction, and rehospitalization for congestive heart failure were similar between the groups., Conclusions and Relevance: This study found that a strategy of immediate coronary angiography does not provide clinical benefit compared with a delayed or selective invasive approach for patients 1 year after resuscitated OHCA of presumed coronary cause and without ST-segment elevation., Trial Registration: ClinicalTrials.gov Identifier: NCT02750462.
- Published
- 2023
- Full Text
- View/download PDF
24. Expanded nursing competencies to improve person-centred care for nursing home residents with complex health needs (Expand-Care): study protocol for an exploratory cluster-randomised trial.
- Author
-
Silies KT, Vonthein R, Pohontsch NJ, Huckle TA, Sill J, Olbrich D, Inkrot S, Frielitz FS, Lühmann D, Scherer M, König I, and Balzer K
- Subjects
- Humans, Aged, Pilot Projects, Control Groups, Ambulatory Care Facilities, Randomized Controlled Trials as Topic, Quality of Life, Patient-Centered Care
- Abstract
Introduction: Older age is associated with multimorbidity, chronic diseases and acute deteriorations and leads to complex care needs. Nursing home residents are more often unnecessarily transferred to emergency departments or hospitals than community dwellers-largely due to a lack of qualified staff and diffusion of responsibility in the institutions. In Germany, only few academically trained nurses work in nursing homes, and their potential roles are unclear. Therefore, we aim to explore feasibility and potential effects of a newly defined role profile for nurses with bachelors' degree or equivalent qualification in nursing homes., Methods and Analysis: A pilot study (Expand-Care) with a cluster-randomised controlled design will be conducted in 11 nursing homes (cluster) in Germany, with an allocation ratio of 5:6 to the intervention or control group, aiming to include 15 residents per cluster (165 participants in total). Nurses in the intervention group will receive training to perform role-related tasks such as case reviews and complex geriatric assessments. We will collect data at three time points (t0 baseline, t1 3 months and t2 6 months after randomisation). We will measure on residents' level: hospital admissions, further health services use and quality of life; clinical outcomes (eg, symptom burden), physical functioning and delivery of care; mortality, adverse clinical incidents and changes in care level. On nurses' level, we will measure perception of the new role profile, competencies and implementation of role-related tasks as part of the process evaluation (mixed methods). An economic evaluation will explore resource use on residents' (healthcare utilisation) and on nurses' level (costs and time expenditure)., Ethics and Dissemination: The ethics committees of the University of Lübeck (Nr. 22-162) and the University Clinic Hamburg-Eppendorf (Nr. 2022-200452-BO-bet) approved the Expand-Care study. Informed consent is a prerequisite for participation. Study results will be published in open-access, peer-reviewed journals and reported at conferences and in local healthcare providers' networks., Trial Registration Number: DRKS00028708., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
25. Radiosurgery for ventricular tachycardia (RAVENTA): interim analysis of a multicenter multiplatform feasibility trial.
- Author
-
Krug D, Zaman A, Eidinger L, Grehn M, Boda-Heggemann J, Rudic B, Mehrhof F, Boldt LH, Hohmann S, Merten R, Buergy D, Fleckenstein J, Kluge A, Rogge A, Both M, Rades D, Tilz RR, Olbrich D, König IR, Siebert FA, Schweikard A, Vonthein R, Bonnemeier H, Dunst J, and Blanck O
- Subjects
- Humans, Stroke Volume, Prospective Studies, Quality of Life, Feasibility Studies, Ventricular Function, Left, Treatment Outcome, Radiosurgery methods, Tachycardia, Ventricular radiotherapy, Tachycardia, Ventricular surgery
- Abstract
Background: Single-session cardiac stereotactic radiation therapy (SBRT) has demonstrated promising results for patients with refractory ventricular tachycardia (VT). However, the full safety profile of this novel treatment remains unknown and very limited data from prospective clinical multicenter trials are available., Methods: The prospective multicenter multiplatform RAVENTA (radiosurgery for ventricular tachycardia) study assesses high-precision image-guided cardiac SBRT with 25 Gy delivered to the VT substrate determined by high-definition endocardial and/or epicardial electrophysiological mapping in patients with refractory VT ineligible for catheter ablation and an implanted cardioverter defibrillator (ICD). Primary endpoint is the feasibility of full-dose application and procedural safety (defined as an incidence of serious [grade ≥ 3] treatment-related complications ≤ 5% within 30 days after therapy). Secondary endpoints comprise VT burden, ICD interventions, treatment-related toxicity, and quality of life. We present the results of a protocol-defined interim analysis., Results: Between 10/2019 and 12/2021, a total of five patients were included at three university medical centers. In all cases, the treatment was carried out without complications. There were no serious potentially treatment-related adverse events and no deterioration of left ventricular ejection fraction upon echocardiography. Three patients had a decrease in VT episodes during follow-up. One patient underwent subsequent catheter ablation for a new VT with different morphology. One patient with local VT recurrence died 6 weeks after treatment in cardiogenic shock., Conclusion: The interim analysis of the RAVENTA trial demonstrates early initial feasibility of this new treatment without serious complications within 30 days after treatment in five patients. Recruitment will continue as planned and the study has been expanded to further university medical centers., Trial Registration Number: NCT03867747 (clinicaltrials.gov). Registered March 8, 2019. Study start: October 1, 2019., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
26. Study protocol for a randomised controlled trial of an e-health stepped care approach for the treatment of internet use disorders versus a placebo condition: the SCAPIT study.
- Author
-
Bischof A, Brandt D, Schlossarek S, Vens M, Rozgonjuk D, Wernicke J, Kannen C, Wölfling K, Dreier M, Salbach H, Basenach L, Mößle T, Olbrich D, König I, Borgwardt S, Montag C, and Rumpf HJ
- Subjects
- Humans, Internet Use, Berlin, Internet, Treatment Outcome, Randomized Controlled Trials as Topic, Cognitive Behavioral Therapy, Motivational Interviewing, Telemedicine
- Abstract
Introduction: Excessive internet use can lead to problems for some individuals. The WHO has introduced Gaming Disorder in the International Classification of Diseases-11 (ICD-11). Previous research has shown that other internet applications can cause serious mental health problems as well. It is important to provide measures of prevention, early intervention and therapy for internet use disorders (IUDs)., Methods and Analysis: The study 'Stepped Care Approach for Problematic Internet use Treatment' is a randomised, two-arm, parallel-group, observer-blind trial. The aim of the study is to investigate if a stepped care approach is effective to reduce symptom severity for IUD. The sample is primarily recruited online with a focus on employees in companies with support of health insurances. After screening, the stepped care approach depends on the success of the previous step-that is, the successful reduction of criteria-and comprise: (1) app-intervention with questionnaires and feedback, (2) two telephone counsellings (duration: 50 min) based on motivational interviewing, (3) online therapy over 17 weeks (15 weekly group sessions, eight individual sessions) based on cognitive-behavioural therapy. A follow-up is conducted after 6 months. A total of 860 participants will be randomised. Hierarchical testing procedure is used to test the coprimary endpoints number of Diagnostic and Statistical Manual of Mental Disorders, fifth edition and ICD-11 criteria. Primary analysis will be performed with a sequential logit model., Ethics and Dissemination: The study has been approved by the Ethics Committees of the Universities of Lübeck (file number: 21-068), Mainz (file number: 2021-15907) and Berlin (file number: 015.2021). Results will be reported in accordance to the CONSORT statement. If the approach is superior to the control condition, it may serve as part of treatment for IUD., Trial Registration Number: DRKS00025994., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
27. Evaluation of Three ISO Estrogen Receptor Transactivation Assays Applied to 52 Domestic Effluent Samples.
- Author
-
Simon E, Riegraf C, Schifferli A, Olbrich D, Bucher T, and Vermeirssen ELM
- Subjects
- Biological Assay methods, Environmental Monitoring methods, Estradiol analysis, Estrogens analysis, Estrogens toxicity, Estrone analysis, Humans, Receptors, Estrogen metabolism, Reference Standards, Saccharomyces cerevisiae metabolism, Transcriptional Activation, Estrogen Receptor alpha metabolism, Water Pollutants, Chemical analysis, Water Pollutants, Chemical toxicity
- Abstract
Estrogens are released to the aquatic environment by wastewater treatment plant (WWTP) effluents and can affect wildlife. In the last three decades, many in vitro assay platforms have been developed to detect and quantify estrogenicity in water. In 2018, the International Organization for Standardization (ISO) standardized protocols became available for three types of in vitro estrogen receptor transactivation assays (ERTAs) detecting estrogenicity in 96-well plates (ISO19040 1-3). Two ERTAs-lyticase Yeast Estrogen Screen (L-YES) and Arxula YES (A-YES)-use genetically modified yeast strains, whereas the third utilizes stably transfected human cells. One human cell based assay is ERα-CALUX, which is based on a genetically modified human bone osteosarcoma cell line. In the present study, we characterized the performance, comparability, and effectiveness of these three ERTAs, including an evaluation involving proposed water quality thresholds (effect-based trigger values [EBTs]). For a robust evaluation, we collected 52 effluent samples over three sampling campaigns at 15 different WWTPs in Switzerland. Estrogen receptor transactivation assay results were correlated and compared with results from chemical analysis targeting known estrogens. The three ERTAs showed comparable data over all campaigns. However, the selection of EBTs plays a significant role in the interpretation and comparison of bioassay results to distinguish between acceptable and unacceptable water quality. Applying a fixed cross-assay EBT for effluent of 4 ng L
-1 resulted in varying numbers of threshold exceedances ranging between zero and four samples depending on the ERTA used. Using assay-specific EBTs showed exceedances in eight samples (ERα-CALUX) and in one sample (A-YES), respectively. Thus, proposed EBTs do not produce similar risk profiles across samples and further refinement of assay-specific EBTs is needed to account for assay-specific differences and to enable the application of ERTAs as effect-based methods in environmental monitoring. Environ Toxicol Chem 2022;41:2512-2526. © 2022 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC., (© 2022 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.)- Published
- 2022
- Full Text
- View/download PDF
28. Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer - results of a randomized phase III trial (RAREST-02).
- Author
-
Rades D, Zwaan I, Cacicedo J, Bruchhage KL, Hakim SG, Olbrich D, Schild SE, Tvilsted S, and Janssen S
- Subjects
- Humans, Head and Neck Neoplasms radiotherapy, Mobile Applications, Mucositis, Radiation Injuries, Radiodermatitis etiology
- Abstract
Background: Radiotherapy of head-and-neck cancer (SCCHN) is often associated with acute toxicity. In a previous trial, daily reminders by staff members to perform skin care resulted in less dermatitis. This randomized trial investigated whether a mobile application can replace these reminders., Methods: Patients were stratified according to tumor site, treatment and center. Fifty-three patients were eligible for per-protocol-set (25 with, 28 without app). Primary endpoint was grade ≥ 2 dermatitis until 60 Gy. Secondary endpoints included dermatitis grade ≥ 2 until end of radiotherapy (EOT), dermatitis grade ≥ 3, and mucositis grade ≥ 2 and ≥ 3., Results: After an interim analysis, the study was terminated (delayed and slow accrual). Until 60 Gy, grade ≥ 2 dermatitis rates were 72% with vs. 82% without app (p = 0.38), grade ≥ 3 dermatitis rates 20% vs. 11% (p = 0.45). Until EOT, grade ≥ 2 and ≥ 3 dermatitis rates were 72% vs. 86% (p = 0.22) and 24% vs. 18% (p = 0.58). Until 60 Gy, grade ≥ 2 and ≥ 3 mucositis rates were 76% vs. 82% (p = 0.58) and 20% vs. 36% (p = 0.20). Until EOT, corresponding mucositis rates were 76% vs. 82% (p = 0.58) and 28% vs. 43% (p = 0.26)., Conclusion: Given the limitations of this trial, the reminder app led to non-significant reduction of grade ≥ 2 dermatitis, grade ≥ 2 mucositis and ≥ 3 mucositis. Additional studies are required to define the value of reminder apps during radiotherapy for SCCHN., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
29. Increasing Seizure Activity During Radiation Treatment for High-grade Gliomas - Final Results of a Prospective Interventional Study.
- Author
-
Rades D, Witteler J, Trillenberg P, Olbrich D, Schild SE, Tvilsted S, and Kjaer TW
- Subjects
- Humans, Prospective Studies, Research, Seizures etiology, Brain Neoplasms pathology, Glioma pathology, Glioma radiotherapy
- Abstract
Background/aim: Little is known regarding seizures during radiotherapy for brain tumors. This prospective study investigated seizure activity in patients irradiated for high-grade gliomas., Patients and Methods: Using a seizure diary, progression of seizure activity was evaluated in 22 patients receiving chemoradiation for grade III (n=1) or IV (n=21) gliomas. Progression was defined as increased frequency of any and/or generalized seizures (>50%) or increased anti-epileptic medication (≥25%). Patients' satisfaction with the diary was assessed using a questionnaire (six scales of 1-7 points). Uni- and multivariable analyses were performed including baseline seizure activity, age, sex, resection, tumor site, performance score, and history of epilepsy/seizures., Results: Ten patients (45%) experienced progression of seizure activity during their radiotherapy course, mainly due to increased seizure frequency (nine patients=41%). Mean values of patients' satisfaction scores ranged between 3.92 and 4.92 points., Conclusion: Radiotherapy of high-grade gliomas can increase seizure activity. Patients require close monitoring to initiate or adjust anti-epileptic medication., (Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
30. Improvement of Sleep Disorders During a Course of Radiotherapy for Breast Cancer - Final Results of the Prospective Interventional RADIO-SLEEP Trial.
- Author
-
Rades D, Narvaez CA, Dziggel L, Splettstösser L, Janssen S, Olbrich D, Schild SE, Tvilsted S, and Kjaer TW
- Subjects
- Female, Humans, Prospective Studies, Research Design, Sleep, Breast Neoplasms complications, Breast Neoplasms psychology, Breast Neoplasms radiotherapy, Sleep Wake Disorders etiology
- Abstract
Background/aim: Upcoming radiotherapy may cause distress and sleep disorders (SDO). This prospective interventional trial investigated SDO during a course of radiotherapy for breast cancer., Patients and Methods: Fifty patients were eligible. The primary endpoint was improvement of SDO after 15 fractions. Additional endpoints included SDO after 5 fractions and at the end of radiotherapy (EOT). Additional characteristics were analysed including use of smartphones/tablets, age, body mass index, performance score, comorbidity score, surgery, distress score, and emotional/ physical/practical problems., Results: After 15 fractions, 38% of patients reported improvement of SDO (p<0.0001). Improvement rates were 22% after 5 fractions (p=0.003) and 39% at EOT (p<0.0001). Moreover, a significant association was observed for lower distress score after 5 fractions., Conclusion: Improvement of SDO occurred more often than expected, most likely due to habituation to radiotherapy. Since SDO did not improve in the majority of patients, timely psychological support should be offered to all patients., (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
31. Biological effect and chemical monitoring of Watch List substances in European surface waters: Steroidal estrogens and diclofenac - Effect-based methods for monitoring frameworks.
- Author
-
Simon E, Duffek A, Stahl C, Frey M, Scheurer M, Tuerk J, Gehrmann L, Könemann S, Swart K, Behnisch P, Olbrich D, Brion F, Aït-Aïssa S, Pasanen-Kase R, Werner I, and Vermeirssen ELM
- Subjects
- Ecosystem, Environmental Monitoring methods, Estradiol analysis, Estrogens analysis, Diclofenac toxicity, Water Pollutants, Chemical analysis
- Abstract
Three steroidal estrogens, 17α-ethinylestradiol (EE2), 17β-estradiol (E2), estrone (E1), and the non-steroidal anti-inflammatory drug (NSAID), diclofenac have been included in the first Watch List of the Water Framework Directive (WFD, EU Directive 2000/60/EC, EU Implementing Decision 2015/495). This triggered the need for more EU-wide surface water monitoring data on these micropollutants, before they can be considered for inclusion in the list of priority substances regularly monitored in aquatic ecosystems. The revision of the priority substance list of the WFD offers the opportunity to incorporate more holistic bioanalytical approaches, such as effect-based monitoring, alongside single substance chemical monitoring. Effect-based methods (EBMs) are able to measure total biological activities (e.g., estrogenic activity or cyxlooxygenase [COX]-inhibition) of specific group of substances (such as estrogens and NSAIDs) in the aquatic environment at low concentrations (pg/L). This makes them potential tools for a cost-effective and ecotoxicologically comprehensive water quality assessment. In parallel, the use of such methods could build a bridge from chemical status assessments towards ecological status assessments by adressing mixture effects for relevant modes of action. Our study aimed to assess the suitability of implementing EBMs in the WFD, by conducting a large-scale sampling and analysis campaign of more than 70 surface waters across Europe. This resulted in the generation of high-quality chemical and effect-based monitoring data for the selected Watch List substances. Overall, water samples contained low estrogenicity (0.01-1.3 ng E2-Equivalent/L) and a range of COX-inhibition activity similar to previously reported levels (12-1600 ng Diclofenac-Equivalent/L). Comparison between effect-based and conventional analytical chemical methods showed that the chemical analytical approach for steroidal estrogens resulted in more (76%) non-quantifiable data, i.e., concentrations were below detection limits, compared to the EBMs (28%). These results demonstrate the excellent and sensitive screening capability of EBMs., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
32. Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation.
- Author
-
Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, Skurk C, Landmesser U, Graf T, Eitel I, Fuernau G, Haake H, Nordbeck P, Hammer F, Felix SB, Hassager C, Engstrøm T, Fichtlscherer S, Ledwoch J, Lenk K, Joner M, Steiner S, Liebetrau C, Voigt I, Zeymer U, Brand M, Schmitz R, Horstkotte J, Jacobshagen C, Pöss J, Abdel-Wahab M, Lurz P, Jobs A, de Waha-Thiele S, Olbrich D, Sandig F, König IR, Brett S, Vens M, Klinge K, and Thiele H
- Subjects
- Aged, Cardiopulmonary Resuscitation, Cause of Death, Coronary Disease complications, Coronary Disease diagnostic imaging, Female, Humans, Kaplan-Meier Estimate, Length of Stay, Male, Middle Aged, Nervous System Diseases etiology, Out-of-Hospital Cardiac Arrest complications, Out-of-Hospital Cardiac Arrest mortality, Out-of-Hospital Cardiac Arrest therapy, ST Elevation Myocardial Infarction diagnostic imaging, Time Factors, Time-to-Treatment, Coronary Angiography, Electrocardiography, Out-of-Hospital Cardiac Arrest diagnostic imaging
- Abstract
Background: Myocardial infarction is a frequent cause of out-of-hospital cardiac arrest. However, the benefits of early coronary angiography and revascularization in resuscitated patients without electrocardiographic evidence of ST-segment elevation are unclear., Methods: In this multicenter trial, we randomly assigned 554 patients with successfully resuscitated out-of-hospital cardiac arrest of possible coronary origin to undergo either immediate coronary angiography (immediate-angiography group) or initial intensive care assessment with delayed or selective angiography (delayed-angiography group). All the patients had no evidence of ST-segment elevation on postresuscitation electrocardiography. The primary end point was death from any cause at 30 days. Secondary end points included a composite of death from any cause or severe neurologic deficit at 30 days., Results: A total of 530 of 554 patients (95.7%) were included in the primary analysis. At 30 days, 143 of 265 patients (54.0%) in the immediate-angiography group and 122 of 265 patients (46.0%) in the delayed-angiography group had died (hazard ratio, 1.28; 95% confidence interval [CI], 1.00 to 1.63; P = 0.06). The composite of death or severe neurologic deficit occurred more frequently in the immediate-angiography group (in 164 of 255 patients [64.3%]) than in the delayed-angiography group (in 138 of 248 patients [55.6%]), for a relative risk of 1.16 (95% CI, 1.00 to 1.34). Values for peak troponin release and for the incidence of moderate or severe bleeding, stroke, and renal-replacement therapy were similar in the two groups., Conclusions: Among patients with resuscitated out-of-hospital cardiac arrest without ST-segment elevation, a strategy of performing immediate angiography provided no benefit over a delayed or selective strategy with respect to the 30-day risk of death from any cause. (Funded by the German Center for Cardiovascular Research; TOMAHAWK ClinicalTrials.gov number, NCT02750462.)., (Copyright © 2021 Massachusetts Medical Society.)
- Published
- 2021
- Full Text
- View/download PDF
33. A prospective interventional study investigating sleep disorders prior to and during adjuvant radiotherapy for breast cancer.
- Author
-
Rades D, Narvaez CA, Dziggel L, Janssen S, Olbrich D, Tvilsted S, and Kjaer TW
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Breast Neoplasms complications, Female, Humans, Middle Aged, Prospective Studies, Radiotherapy, Adjuvant adverse effects, Risk Factors, Severity of Illness Index, Sleep Wake Disorders diagnosis, Sleep Wake Disorders etiology, Smartphone statistics & numerical data, Young Adult, Breast Neoplasms therapy, Sleep Wake Disorders epidemiology
- Abstract
Background: Most breast cancer patients with non-metastatic disease receive adjuvant local or loco-regional radiotherapy. To be scheduled for irradiation may cause distress and fears that can lead to sleep disorders. Few reports focused on sleep problems in patients assigned to radiotherapy. This study evaluates the course of sleep disorders during adjuvant radiotherapy for primary breast cancer and potential risk factors including the use of smartphones or tablets at bedtime., Methods: The main goal is the evaluation of sleep disorders prior to radiotherapy and after 15 fractions of radiotherapy. A potential effect of habituation to the procedure of radiotherapy can be assumed that will likely lead to improvement (decrease) of sleep disorders. Improvement of sleep disorders (compared to baseline before radiotherapy) is defined as decrease of the severity of sleep disorders by ≥2 points on a patient self-rating scale (0 = no problems; 10 = maximum problems) or decrease of distress caused by sleep disorders by ≥2 points on a self-rating scale (0 = no distress; 10 = maximum distress) or reduction of the dose of sleeping drugs by ≥25%. Additional endpoints include sleep disorders after 5 fractions and at the end of radiotherapy. Moreover, potential risk factors including the use of smartphones or tablets at bedtime are evaluated. Fifty-one patients (48 plus potential drop-outs) are required. With this sample size, a one-sample binomial test with a one-sided significance level of 2.5% has a power of 80% to yield statistical significance, if the rate of patients with improvement of sleep disorders is 25% (rate under the alternative hypothesis) and assuming that a decrease of ≤10% has to be judged as a random, non-causal change in this uncontrolled study setting (null hypothesis)., Discussion: If a decrease of sleep disorders during the course of radiotherapy is shown, this aspect should be included in the pre-radiotherapy consent discussion with the patients. Moreover, identification of additional risk factors will likely lead to earlier psychological support. If the use of smartphones or tablets at bedtime is a risk factor, patients should be advised to change this behavior., Trial Registration: clinicaltrials.gov (NCT04879264; URL: https://clinicaltrials.gov/show/NCT04879264 ); registered on 7th of May, 2021., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
34. Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial.
- Author
-
Krug D, Vonthein R, Schreiber A, Boicev AD, Zimmer J, Laubach R, Weidner N, Dinges S, Hipp M, Schneider R, Weinstrauch E, Martin T, Hörner-Rieber J, Olbrich D, Illen A, Heßler N, König IR, Dellas K, and Dunst J
- Subjects
- Dose Fractionation, Radiation, Female, Humans, Logistic Models, Radiotherapy, Adjuvant methods, Breast Neoplasms pathology, Breast Neoplasms radiotherapy, Radiation Dose Hypofractionation
- Abstract
Purpose: Hypofractionated radiotherapy is the standard of care for adjuvant whole breast radiotherapy (RT). However, adoption has been slow. The indication for regional nodal irradiation has been expanded to include patients with 0-3 involved lymph nodes. We investigated the impact of the publication of the updated German S3 guidelines in 2017 on adoption of hypofractionation and enrollment of patients with lymph node involvement within a randomized controlled phase III trial., Methods: In the experimental arm of the HYPOSIB trial (NCT02474641), hypofractionated RT with simultaneous integrated boost (SIB) was used. In the standard arm, RT could be given as hypofractionated RT with sequential boost (HF
seq ), normofractionated RT with sequential boost (NFseq ), or normofractionated RT with SIB (NFSIB ). The cutoff date for the updated German S3 guidelines was December 17, 2017. Temporal trends were analyzed by generalized linear regression models. Multiple logistic regression models were used to investigate the influence of time (prior to/after guideline) and setting (university hospital/other institutions) on the fractionation patterns., Results: Enrollment of patients with involved lymph nodes was low throughout the trial. Adoption of HFseq increased over time and when using the guideline publication date as cutoff. Results of the multiple logistic regressions showed an interaction between time and setting. Furthermore, the use of HFseq was significantly more common in university hospitals., Conclusion: The use of HFseq in the standard arm increased over the course of the HYPOSIB trial and after publication of the S3 guideline update. This was primarily driven by patients treated in university hospitals. Enrolment of patients with lymph node involvement was low throughout the trial., (© 2020. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
35. A prospective interventional study evaluating seizure activity during a radiotherapy course for high-grade gliomas (SURF-ROGG).
- Author
-
Rades D, Witteler J, Olbrich D, Trillenberg P, Schild SE, Tvilsted S, and Kjaer TW
- Subjects
- Anticonvulsants therapeutic use, Brain Neoplasms radiotherapy, Chemoradiotherapy, Cranial Irradiation methods, Disease Management, Disease Susceptibility, Electroencephalography, Female, Glioma radiotherapy, Humans, Male, Neoplasm Grading, Neoplasm Staging, Seizures therapy, Symptom Assessment, Treatment Outcome, Brain Neoplasms complications, Brain Neoplasms pathology, Cranial Irradiation adverse effects, Glioma complications, Glioma pathology, Seizures diagnosis, Seizures etiology
- Abstract
Background: Gliomas are often associated with symptoms including seizures. Most patients with high-grade gliomas are treated with radiotherapy or radio-chemotherapy. Since irradiation causes inflammation, it may initially aggravate symptoms. Studies focusing on seizure activity during radiotherapy for gliomas are not available. Such knowledge may improve patient monitoring and anti-epileptic treatment. This study evaluates seizure activity during radiotherapy for high-grade gliomas., Methods: The primary objective this prospective interventional study is the evaluation of seizure activity during a course of radiotherapy for high-grade gliomas. Progression of seizure activity is defined as increased frequency of seizures by > 50%, increased severity of seizures, or initiation/increase by ≥25% of anti-epileptic medication. Seizure frequency up to 6 weeks following radiotherapy and electroencephalography activity typical for epilepsy will also be evaluated. Patients keep a seizure diary during and up to 6 weeks following radiotherapy. Every day, they will document number (and type) of seizures and anti-epileptic medication. Once a week, the findings of the diary are checked and discussed with a neurologist to initiate or adjust anti-epileptic medication, if necessary. Patients complete a questionnaire regarding their satisfaction with the seizure diary. If the dissatisfaction rate is > 40%, the seizure diary will be considered not suitable for the investigated indication. Thirty-five patients (32 patients plus drop-outs) should be enrolled. With this sample size, a one-sample binomial test with a one-sided significance level of 2.5% has a power of 80% to yield statistical significance, if the rate of patients with progression of seizure activity is 30% (rate under the alternative hypothesis), assuming a 'natural' background progression-rate of 10% without radiotherapy (null hypothesis)., Discussion: If an increase in seizure activity during a course of radiotherapy for high-grade glioma occurs, the findings of this study may pave the way for a larger prospective trial and will likely lead to closer patient monitoring and better anti-epileptic treatment., Trial Registration: clinicaltrials.gov ( NCT04552756 ); registered on 16th of September, 2020.
- Published
- 2021
- Full Text
- View/download PDF
36. Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA).
- Author
-
Krug D, Vonthein R, Illen A, Olbrich D, Barkhausen J, Richter J, Klapper W, Schmalz C, Rody A, Maass N, Bauerschlag D, Heßler N, König IR, Dellas K, and Dunst J
- Abstract
Background: Several recent randomized therapeutic exploratory trials demonstrated improvement of progression-free survival and in some even overall survival using stereotactic body radiotherapy in patients with oligometastatic disease. However, only very few patients enrolled in these trials had breast cancer, and results from confirmatory trials are lacking., Methods/design: The OLIGOMA-trial is a randomized controlled multi-national multi-center therapeutic confirmatory trial studying the role of local ablative radiotherapy as an additive treatment in patients with oligometastatic breast cancer receiving standard systemic therapy. Patients will be randomized 1:1 to standard systemic therapy according to national guidelines with or without radiotherapy to all metastatic sites. Randomization will be stratified according to type and line of systemic therapy, which has to be determined by a multidisciplinary tumor board before enrollment. Patients with up to five metastatic lesions are eligible, including patients with up to three brain metastases (only in case of extracranial disease) and with locoregional recurrence (only in case of additional metastatic lesions). In the standard arm, palliative radiotherapy to symptomatic metastases is permitted if at least one lesion remains untreated. The co-primary endpoints are progression-free survival and quality of life. The primary hypothesis is that progression-free survival in the experimental arm will be superior to the standard arm while simultaneously demonstrating non-inferiority of quality of life at 12 weeks after randomization. Secondary endpoints are feasibility, overall survival, toxicity, quality of life and patient satisfaction. A translational sub-study with collection of ctDNA will be conducted., Discussion: The OLIGOMA-trial will provide high level evidence on the use of and benefit from local ablative radiotherapy for patients with oligometastatic breast cancer., Trial Registration: The OLIGOMA-trial is registered at clinicialtrials.gov under the identification NCT04495309. The related information was first posted on July 31st 2020., Competing Interests: DK has received honoraria from Merck Sharp & Dome outside the submitted work. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
37. Efficacy, Treatment Characteristics, and Biopsychological Mechanisms of Music-Listening Interventions in Reducing Pain (MINTREP): Study Protocol of a Three-Armed Pilot Randomized Controlled Trial.
- Author
-
Feneberg AC, Kappert MB, Maidhof RM, Doering BK, Olbrich D, and Nater UM
- Abstract
Background: Pain can severely compromise a person's overall health and well-being. Music-listening interventions have been shown to alleviate perceived pain and to modulate the body's stress-sensitive systems. Despite the growing evidence of pain- and stress-reducing effects of music-listening interventions from experimental and clinical research, current findings on music-induced analgesia are inconclusive regarding the role of specific treatment characteristics and the biopsychological mechanisms underlying these effects. Objective: The overall aim of this pilot randomized controlled trial is to test and compare the differential effects of frequency-modulated and unmodulated music (both researcher-selected) on experimentally induced perception of acute pain and to test the efficacy of the interventions in reducing biological and subjective stress levels. Moreover, these two interventions will be compared to a third condition, in which participants listen to self-selected unmodulated music. Methods and Analysis: A total of 90 healthy participants will be randomly allocated to one of the three music-listening intervention groups. Each intervention encompasses 10 sessions of music listening in our laboratory. Frequency-modulation will involve stepwise filtering of frequencies in the audible range of 50-4,000 Hz. Acute pain will be induced via the cold pressor test. Primary (i.e., pain tolerance, perceived pain intensity) and secondary (i.e., heart rate variability, electrodermal activity, hair cortisol, subjective stress) outcomes will be measured at baseline, post, and follow-up. In addition, intermittent measurements as well as a follow-up assessment and a range of tertiary measures (e.g., music-induced emotions) are included. Discussion: This is the first study to systematically test and compare the effects of music frequencies along with the control over music selection, both of which qualify as central treatment characteristics of music-listening interventions. Results will be highly informative for the design of subsequent large-scale clinical trials and provide valuable conclusions for the implementation of music-listening interventions for the reduction of perceived pain. Clinical Trial Registration: Clinical Trials Database of the U.S. National Library of Medicine: Identifier NCT02991014., (Copyright © 2020 Feneberg, Kappert, Maidhof, Doering, Olbrich and Nater.)
- Published
- 2020
- Full Text
- View/download PDF
38. Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA).
- Author
-
Blanck O, Buergy D, Vens M, Eidinger L, Zaman A, Krug D, Rudic B, Boda-Heggemann J, Giordano FA, Boldt LH, Mehrhof F, Budach V, Schweikard A, Olbrich D, König IR, Siebert FA, Vonthein R, Dunst J, and Bonnemeier H
- Subjects
- Feasibility Studies, Female, Germany, Humans, Male, Prospective Studies, Tachycardia, Ventricular physiopathology, Treatment Outcome, Catheter Ablation methods, Quality of Life, Radiosurgery methods, Tachycardia, Ventricular therapy
- Abstract
Background: Single-session high-dose stereotactic radiotherapy (radiosurgery) is a new treatment option for otherwise untreatable patients suffering from refractory ventricular tachycardia (VT). In the initial single-center case studies and feasibility trials, cardiac radiosurgery has led to significant reductions of VT burden with limited toxicities. However, the full safety profile remains largely unknown., Methods/design: In this multi-center, multi-platform clinical feasibility trial which we plan is to assess the initial safety profile of radiosurgery for ventricular tachycardia (RAVENTA). High-precision image-guided single-session radiosurgery with 25 Gy will be delivered to the VT substrate determined by high-definition endocardial electrophysiological mapping. The primary endpoint is safety in terms of successful dose delivery without severe treatment-related side effects in the first 30 days after radiosurgery. Secondary endpoints are the assessment of VT burden, reduction of implantable cardioverter defibrillator (ICD) interventions [shock, anti-tachycardia pacing (ATP)], mid-term side effects and quality-of-life (QoL) in the first year after radiosurgery. The planned sample size is 20 patients with the goal of demonstrating safety and feasibility of cardiac radiosurgery in ≥ 70% of the patients. Quality assurance is provided by initial contouring and planning benchmark studies, joint multi-center treatment decisions, sequential patient safety evaluations, interim analyses, independent monitoring, and a dedicated data and safety monitoring board., Discussion: RAVENTA will be the first study to provide the initial robust multi-center multi-platform prospective data on the therapeutic value of cardiac radiosurgery for ventricular tachycardia., Trial Registration Number: NCT03867747 (clinicaltrials.gov). Registered March 8, 2019. The study was initiated on November 18th, 2019, and is currently recruiting patients.
- Published
- 2020
- Full Text
- View/download PDF
39. Pneumonitis after radiotherapy for lung cancer (PARALUC): an interventional study to create a symptom-based scoring system for identification of patients developing radiation pneumonitis.
- Author
-
Rades D, Werner EM, Glatzel E, Eggert MC, Olbrich D, Tvilsted S, and Bohnet S
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mobile Applications, ROC Curve, Radiation Pneumonitis etiology, Young Adult, Lung Neoplasms radiotherapy, Radiation Pneumonitis diagnosis, Severity of Illness Index
- Abstract
Background: Pneumonitis is a possible side effect of radiotherapy for lung cancer. Since it can occur up to several months following treatment, symptoms may not be associated with previous radiotherapy, and pneumonitis can become severe before diagnosed. This study aimed to develop a symptom-based scoring system to contribute to earlier detection of radiation pneumonitis requiring medical intervention (grade ≥ 2)., Methods: Patients irradiated for lung cancer complete a paper-based questionnaire (symptom-based score) during and up to 24 weeks following radiotherapy. Patients rate symptoms potentially associated with pneumonitis, and scoring points are assigned to severity of these symptoms. Sum scores are used to identify radiation pneumonitis. If radiation pneumonitis is suspected, patients undergo standard diagnostic procedures. If grade ≥ 2 pneumonitis is confirmed, medical intervention is indicated. The discriminative power of the score will be assessed by calculating the area under the receiver operating characteristic curve (AUC). If statistical significance of the AUC is reached, the optimal sum score to predict radiation pneumonitis will be established, which is defined as a cut-off value with sensitivity ≥90% and specificity ≥80%. Assuming a ratio between patients without and with pneumonitis of 3.63, a sample size of 93 patients is required in the full analysis set to yield statistical significance at the level of 5% with a power of 90% if the AUC under the alternative hypothesis is at least 0.9. Considering potential drop-outs, 98 patients should be recruited. If > 20% of patients are not satisfied with the score, modification is required. If the dissatisfaction rate is > 40%, the score is considered not useful. In 10 patients, functionality of a mobile application will be tested in addition to the paper-based questionnaire., Discussion: If an optimal cut-off score resulting in sufficiently high sensitivity and specificity can be identified and the development of a symptom-based scoring system is successful, this tool will contribute to better identification of patients experiencing pneumonitis after radiotherapy for lung cancer., Trial Registration: Clinicaltrials.gov ( NCT04335409 ); registered on 2nd of April, 2020.
- Published
- 2020
- Full Text
- View/download PDF
40. Radiotherapy-related skin toxicity (RAREST-02): A randomized trial testing the effect of a mobile application reminding head-and-neck cancer patients to perform skin care (reminder app) on radiation dermatitis.
- Author
-
Rades D, Narvaez CA, Doemer C, Janssen S, Olbrich D, Tvilsted S, Conde-Moreno AJ, and Cacicedo J
- Subjects
- Humans, Quality of Life, Radiodermatitis etiology, Radiotherapy adverse effects, Randomized Controlled Trials as Topic, Stomatitis etiology, Head and Neck Neoplasms radiotherapy, Mobile Applications, Radiodermatitis prevention & control, Skin Care methods, Stomatitis prevention & control
- Abstract
Background: Radiotherapy of head-and-neck cancer can be associated with significant toxicities including dermatitis and oral mucositis. Severe toxicities may require interruptions of the radiation treatment associated with impairment of the patients' prognoses. This study will investigate whether the addition of a reminder app to standard care can reduce dermatitis and oral mucositis rates during radiotherapy in these patients., Methods: This randomized trial compares standard care supported by a reminder app (Arm A) to standard care alone (Arm B) with respect to grade ≥ 2 radiation dermatitis and oral mucositis at 60 Gy of radiotherapy, the minimum planned dose for patients receiving definitive or adjuvant radiotherapy for locally advanced head- and-neck cancer. Moreover, radiation-induced dermatitis and oral mucositis grade ≥ 3 at 60 Gy and both grade ≥ 2 and grade ≥ 3 at the end of radiation treatment (EOT) will be evaluated, as well as quality of life and pain. According to sample size calculations, 80 patients are required per arm within the full analysis set. Taking into account that 5% of patients will not qualify for full analysis set, 168 patients should be randomized. The impact of the reminder app will be considered clinically relevant, if the rates of grade ≥ 2 radiation dermatitis (primary endpoint) and oral mucositis (secondary endpoint) can be reduced by 20%., Discussion: If the addition of a reminder app to standard care will lead to a significant reduction of radiation dermatitis and oral mucositis, it could become a helpful tool for patients with head-and-neck cancer during radiotherapy., Trial Registration: clinicaltrials.gov (NCT04110977). Registered on September 27, 2019. First patient is planned to be included in December 2019.
- Published
- 2020
- Full Text
- View/download PDF
41. The nature of obligation's special force.
- Author
-
Olbrich D
- Subjects
- Coercion, Morals
- Abstract
Tomasello's characterization of obligation as demanding and coercive is not an implication of the centrality of collaborative commitment. Not only is this characterization contentious, it appears to be falsified in some cases of personal conviction. The theory would be strengthened if the nature of obligation's force and collaborative commitment were directly linked, possibly through Tomasello's notions of identity and identification.
- Published
- 2020
- Full Text
- View/download PDF
42. Precision Radiation Therapy for Metastatic Spinal Cord Compression: Final Results of the PRE-MODE Trial.
- Author
-
Rades D, Cacicedo J, Conde-Moreno AJ, Segedin B, But-Hadzic J, Groselj B, Kevlishvili G, Lomidze D, Ciervide-Jurio R, Rubio C, Perez-Romasanta LA, Alvarez-Gracia A, Olbrich D, Doemer C, Schild SE, and Hollaender NH
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Treatment Outcome, Precision Medicine, Spinal Cord Compression radiotherapy
- Abstract
Objective: To investigate precision radiation therapy for metastatic spinal cord compression and compare it to conventional radiation therapy., Methods and Materials: In a multicenter phase 2 study, 40 patients received 5 Gy × 5 fractions of precision radiation therapy (38 volume modulated arc therapy, 2 intensity modulated radiation therapy) for metastatic spinal cord compression and were evaluated for local progression-free survival (LPFS), motor function, ambulatory status, sensory function, sphincter dysfunction, pain, distress, overall survival (OS), and toxicity. Maximum spinal cord dose was 101.5% (myelopathy risk, <0.03%) of the prescription dose. Patients were compared with a historical control group conventionally irradiated with 4 Gy × 5 fractions (propensity score analysis). The equivalent dose in 2 Gy-fractions of 5 Gy × 5 fractions is similar to 3 Gy × 10 fractions, which results in better LPFS than 4 Gy × 5 fractions. It was assumed that 5 Gy × 5 fractions is also superior to 4 Gy × 5 fractions for LPFS. (ClinicalTrials.gov-identifier: NCT03070431) RESULTS: Six-month rates of LPFS and OS were 95.0% and 42.6%, respectively. Improvement of motor function occurred in 24 patients (60%). Thirty-three patients (82.5%) were ambulatory after radiation therapy. Eight of 16 patients (50.0%) with sensory deficits improved. Pain and distress relief were reported by 61.9% and 54.2% of patients 1 month after radiation therapy. Grade 3 toxicities occurred in 1 patient and grade 2 toxicities in another 3 patients. Of the control group, 664 patients qualified for the propensity score analysis; 5 Gy × 5 fractions was significantly superior to 4 Gy × 5 fractions with regard to LPFS (P = .026) but not motor function (P = .51) or OS (P = .82)., Conclusions: Precision radiation therapy with 5 Gy × 5 fractions was well tolerated and effective and appeared superior to 4 Gy × 5 fractions in terms of LPFS. The retrospective nature of the historic control group, which might have led to a hidden selection bias, needs to be considered when interpreting the results., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
43. [Efficacy of Disease Management Programs Asthma and COPD? Results of a Cross-Sectional Study].
- Author
-
Kanniess F, Krockenberger K, Oepen P, Hedrich R, Olbrich D, Hessler N, Ziegler A, and Langer-Brauburger B
- Subjects
- Cross-Sectional Studies, Disease Management, Germany, Humans, Prospective Studies, Asthma diagnosis, Asthma therapy, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive therapy
- Abstract
Background: The efficacy of the German disease management programs (DMP) asthma and chronic obstructive pulmonary disease (COPD) cannot be shown with the legally bound documentations. Studies with control groups are rare. Aim of this work was to investigate in a cross-sectional study whether the disease control differs in participants (DMP+) and non-participants (DMP - ) of the DMPs asthma and COPD., Methods: The study was a prospective multicenter cross-sectional study. Primary endpoints were the Asthma Control Test™ (ACT) in the asthma part of the study and the COPD Assessment Test™ (CAT) for the COPD part., Results: A total of 1038 asthma patients and 846 COPD patients were included, of whom about 70 % participated in the corresponding DMP. The ACT total score was higher in asthma DMP+ patients than in DMP- patients (mean difference 0.86; 95 % CI: 0.29 - 1.43;p = 0.003), but not clinically relevant. For COPD there was no clinically relevant difference in COPD disease impact (0.52; 95 % CI: - 0.71 - 1.75; p = 0.405). Although DMP patients had to be enrolled in the respective DMP for at least one year, only 60 % of these patients had participated in a structured education. We did not observe a difference in disease control in DMP patients who respectively participated and did not participate in a structured education., Discussion: There was no clinically relevant difference in disease control between DMP+ and DMP- patients. The efficacy of DMPs has been demonstrated internationally in randomized controlled trials. Randomized controlled trials should be conducted in Germany for demonstrating efficacy of DMPs asthma and COPD., Registration: drks.de, DRKS00007664, Registration date: Jan 15, 2015., Competing Interests: Diese Studie wurde durch die Mundipharma GmbH finanziert. P. O. und B. L-B. sind Mitarbeiterinnen der Mundipharma GmbH. F. K. und A. Z. haben Beraterverträge mit der Mundipharma GmbH. A. Z. ist Mitglied der Schriftleitung der Dtsch Med Wochenschr., (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2020
- Full Text
- View/download PDF
44. Mental health problem or workplace problem or something else: what contributes to work perception?
- Author
-
Muschalla B, Henning A, Haake TW, Cornetz K, and Olbrich D
- Subjects
- Anxiety, Humans, Perception, Mental Disorders rehabilitation, Mental Health, Return to Work, Workplace
- Abstract
Purpose: Work perception is an important predictor for work ability and, therefore, of interest for rehabilitation. Until now it is unclear to which extent different psychological aspects explain work perception. This study investigates in which way workplace problems on the one hand, and mental health and coping on the other hand, contribute to work perception. Methods: A heterogeneous sample of 384 persons in working age with and without mental health problems was recruited. Participants gave self-reports on workplace problems, mental health problems, work-coping, work-anxiety, and work perception. Results: Persons with mental health problems and workplace problems (M + W) perceive the highest degree of work demands, followed by persons with workplace problems but without mental health problems (NM + W). Work-anxiety appeared as the strongest factor explaining perception of high work demands, whereas general mental health problems did not contribute significantly to variance explanation. Conclusions: Persons with specific mental health problems in terms of work-anxiety may be expected to perceive higher work demands. They may be detected when asking for work perception, e.g., within the frame of return-to-work interventions in rehabilitation, or in occupational health settings by mental hazard analysis.Implications for rehabilitationWork perception is an important predictor for work ability. Work-anxiety plays a key role for work perception. Thus, work perception and work anxiety should be explored in the diagnostic phase of rehabilitation treatments.Work-anxiety should be considered not only in rehabilitation diagnostics and interventions in clinical settings, but considered in preventive activities at work: Self-ratings on work-anxiety and work perception (instead of general wellbeing) may be included in assessments for workplace exploration, or mental hazard analysis. They give hints concerning concrete work-related health problems.
- Published
- 2020
- Full Text
- View/download PDF
45. Radiotherapy for metastatic spinal cord compression with increased radiation doses (RAMSES-01): a prospective multicenter study.
- Author
-
Rades D, Hansen O, Jensen LH, Dziggel L, Staackmann C, Doemer C, Cacicedo J, Conde-Moreno AJ, Segedin B, Ciervide-Jurio R, Rubio-Rodriguez C, Perez-Romasanta LA, Alvarez-Gracia A, Dennis K, Ferrer-Albiach C, Navarro-Martin A, Lopez-Campos F, Jankarashvili N, Janssen S, Olbrich D, and Holländer NH
- Subjects
- Clinical Trials as Topic, Dose-Response Relationship, Radiation, Humans, Radiation Injuries, Radiosurgery adverse effects, Radiosurgery methods, Radiotherapy, Intensity-Modulated adverse effects, Radiotherapy, Intensity-Modulated methods, Spinal Cord Compression pathology, Survival Analysis, Dose Fractionation, Radiation, Spinal Cord Compression radiotherapy, Spinal Neoplasms radiotherapy, Spinal Neoplasms secondary
- Abstract
Background: Patients with metastatic spinal cord compression (MSCC) and favorable survival prognoses can benefit from radiation doses greater than 30Gy in 10 fractions in terms of improved local progression-free survival (LPFS) and overall survival (OS)., Methods/design: This prospective study mainly investigates LPFS after precision radiotherapy (volumetric modulated arc therapy or stereotactic body radiotherapy) with 18 × 2.33Gy in 3.5 weeks. LPFS is defined as freedom from progression of motor deficits during radiotherapy and an in-field recurrence of MSCC following radiotherapy. The maximum relative dose allowed to the spinal cord is 101.5% of the prescribed dose, resulting in an equivalent dose in 2Gy-fractions (EQD2) for radiation myelopathy is 45.5Gy, which is below the tolerance dose of 50Gy according to the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC). The EQD2 of this regimen for tumor cell kill is 43.1Gy, which is 33% higher than for 30Gy in 10 fractions (EQD2 = 32.5Gy). Primary endpoint is LPFS at 12 months after radiotherapy. Secondary endpoints include the effect of 18 × 2.33Gy on motor function, ambulatory status, sensory function, sphincter dysfunction, LPFS at other follow-up times, overall survival, pain relief, relief of distress and toxicity. Follow-up visits for all endpoints will be performed directly and at 1, 3, 6, 9 and 12 months after radiotherapy. A total of 65 patients are required for the prospective part of the study. These patients will be compared to a historical control group of at least 235 patients receiving conventional radiotherapy with 10x3Gy in 2 weeks., Discussion: If precision radiotherapy with 18 × 2.33Gy results in significantly better LPFS than 10x3Gy of conventional radiotherapy, this regimen should be strongly considered for patients with MSCC and favorable survival prognoses., Trial Registration: Clinicaltrials.gov NCT04043156. Registered 30-07-2019.
- Published
- 2019
- Full Text
- View/download PDF
46. A randomized trial (RAREST-01) comparing Mepitel® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).
- Author
-
Rades D, Narvaez CA, Splettstößer L, Dömer C, Setter C, Idel C, Ribbat-Idel J, Perner S, Bartscht T, Olbrich D, Schild SE, and Carl J
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Silicones adverse effects, Head and Neck Neoplasms radiotherapy, Radiodermatitis prevention & control, Silicones therapeutic use, Squamous Cell Carcinoma of Head and Neck radiotherapy
- Abstract
Mepitel® Film (MEP) and standard care (STD) were compared for radiation dermatitis in SCCHN patients. This trial was stopped prematurely since13/28 patients did not tolerate MEP. Grade ≥2 dermatitis: 34.8% (MEP) vs. 35.7% (STD) at 50 Gy, 65.2% vs. 59.3% at 60 Gy. MEP was unsatisfactorily tolerated and appeared not superior (NCT03047174)., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
47. An omics-based strategy using coenzyme Q10 in patients with Parkinson's disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial.
- Author
-
Prasuhn J, Brüggemann N, Hessler N, Berg D, Gasser T, Brockmann K, Olbrich D, Ziegler A, König IR, Klein C, and Kasten M
- Abstract
Background: This study focuses on genetically stratified subgroups of Parkinson's disease patients (PD) with an enrichment of risk variants in mitochondrial genes,who might benefit from treatment with the "mitochondrial enhancer" coenzyme Q10 (156 mg coenzyme Q10/d [QuinoMit Q10® Fluid] over six months). The study will be performed in a double-blind, randomized, and placebo-controlled parallel group manner., Methods: PD patients will be specifically identified and assigned to treatment groups stratified by their genetic "mitochondrial risk burden" and consequently expected mitochondrial dysfunction and treatment response to coenzyme Q10 (homozygous or compound heterozygous Parkin/PINK1 mutation carriers [P++], heterozygous Parkin/PINK1 mutation carriers [P+], "omics" positive [omics+], and "omics" negative PD patients [omics-]). The primary endpoint is the change in motor symptoms over six months (as measured by the change in the motor subscore of the MDS-UPDRS). Secondary clinical endpoints include motor fluctuations, non-motor symptoms, results of magnetic resonance imaging of brain energy metabolism (31P-magnetic resonance spectroscopy imaging), and changes in structural and functional brain anatomy (MRI)., Perspective: This study may be a first step towards a successful prediction of treatment response based on the genetic status of PD patients and translate progress in molecular genetics into personalized patient care. Further, magnetic resonance spectroscopy imaging may help quantify increased energy supply objectively and within a brief time after the start of treatment. Therefore, the potential of MRSI also for other studies addressing brain energy metabolism may will be assessed., Trial Registration: This study was registered at the German Clinical Trial Registry (DRKS, DRKS00015880) on November 15th, 2018., Competing Interests: Competing interestsThe authors declare that they have no competing interests., (© The Author(s) 2019.)
- Published
- 2019
- Full Text
- View/download PDF
48. Solid-phase extraction of estrogens and herbicides from environmental waters for bioassay analysis-effects of sample volume on recoveries.
- Author
-
Simon E, Schifferli A, Bucher TB, Olbrich D, Werner I, and Vermeirssen ELM
- Subjects
- Bacteria drug effects, Chlorophyta drug effects, Chromatography, Liquid methods, Environmental Exposure adverse effects, Environmental Exposure analysis, Estrogens toxicity, Herbicides toxicity, Rivers chemistry, Tandem Mass Spectrometry methods, Toxicity Tests methods, Wastewater analysis, Water Pollutants, Chemical toxicity, Environmental Monitoring methods, Estrogens isolation & purification, Herbicides isolation & purification, Solid Phase Extraction methods, Water Pollutants, Chemical isolation & purification
- Abstract
Ecotoxicological screening of surface waters can involve multiple analyses using multiple bioassay and chemical analytical methods that require enriched samples to reach low concentrations. Such broad screening of the same sample necessitates sufficient sample volume-typically several liters-to produce a sufficient amount of enriched sample. Often, this is achieved by performing parallel solid-phase extractions (SPE) where extracts are combined into a pool-this is a laborious process. In this study, we first validated our existing SPE method for the chemical recovery of an extended set of compounds. We spiked four estrogenic compounds and 11 herbicides to samples from independent rivers (1 L) and wastewater treatment plant effluents (0.5 L). Then, we investigated the effect of increased sample loading of the SPE cartridges on both chemical and biological recoveries by comparing the validated volumes with four times larger sample volumes (i.e., 4 L river water and 2 L effluent). Samples were analyzed by LC-MS/MS and three bioassays: an estrogen receptor transactivation assay (ERα-CALUX), the combined algae test, and a bacterial bioluminescence inhibition assay. Our existing SPE method was found to be suitable for enriching the extended set of estrogens and herbicides in river water and effluents with near to perfect chemical recoveries (~ 100%), except for the herbicide metribuzin (46 ± 19%). In the large volume river and effluent samples, the biological activities and concentrations of the spiked compounds were between 87 and 104% of those measured with the lower sample loading, which is adequate. In addition, the ratio between the large and original volume SPE method for the non-target endpoint (bacterial bioluminescence inhibition) was acceptable (on average 82 ± 9%). Results indicate that our current water extraction method can be applied to up to four times larger sample volumes, resulting in four times more extract volumes, without significant reductions in recoveries for the tested estrogens and herbicides. Graphical abstract ᅟ.
- Published
- 2019
- Full Text
- View/download PDF
49. Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial.
- Author
-
Desch S, Freund A, Graf T, Fichtlscherer S, Haake H, Preusch M, Hammer F, Akin I, Christ M, Liebetrau C, Skurk C, Steiner S, Voigt I, Schmitz R, Mudra H, Ledwoch J, Menck N, Horstkotte J, Pels K, Lahmann AL, Otto S, Lenk K, Ohlow MA, Hassager C, Nordbeck P, Zeymer U, Jobs A, de Waha-Thiele S, Olbrich D, König I, Klinge K, and Thiele H
- Subjects
- Cause of Death trends, Europe epidemiology, Follow-Up Studies, Humans, Out-of-Hospital Cardiac Arrest mortality, Out-of-Hospital Cardiac Arrest therapy, Prospective Studies, Survival Rate trends, Time Factors, Cardiopulmonary Resuscitation methods, Coronary Angiography methods, Electrocardiography, Out-of-Hospital Cardiac Arrest diagnosis, Time-to-Treatment, Triage methods
- Abstract
Patients experiencing out-of-hospital cardiac arrest (OHCA) without ST-segment elevation are a heterogenic group with a variety of underlying causes. Up to one-third of patients display a significant coronary lesion compatible with myocardial infarction as OHCA trigger. There are no randomized data on patient selection and timing of invasive coronary angiography after admission. METHODS AND RESULTS: The TOMAHAWK trial randomly assigns 558 patients with return of spontaneous circulation after OHCA with no obvious extracardiac origin of cardiac arrest and no ST-segment elevation/left bundle-branch block on postresuscitation electrocardiogram to either immediate coronary angiography or initial intensive care assessment with delayed/selective angiography in a 1:1 ratio. The primary end point is 30-day all-cause mortality. Secondary analyses will be performed with respect to initial rhythm, electrocardiographic patterns, myocardial infarction as underlying cause, neurological outcome, as well as clinical and laboratory markers. Clinical follow-up will be performed at 6 and 12 months. Safety end points include bleeding and stroke. CONCLUSION: The TOMAHAWK trial will address the unresolved issue of timing and general indication of angiography after OHCA without ST-segment elevation., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
50. [Efficacy of Disease Management Programs Asthma and COPD? Results of a Cross-Sectional Study].
- Author
-
Kanniess F, Krockenberger K, Oepen P, Hedrich R, Olbrich D, Hessler N, Ziegler A, and Langer-Brauburger B
- Subjects
- Cross-Sectional Studies, Humans, Prospective Studies, Asthma diagnosis, Asthma therapy, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive therapy
- Abstract
Background: The efficacy of the German disease management programs (DMP) asthma and chronic obstructive pulmonary disease (COPD) cannot be shown with the legally bound documentations. Studies with control groups are rare. Aim of this work was to investigate in a cross-sectional study whether the disease control differs in participants (DMP+) and non-participants (DMP-) of the DMPs asthma and COPD., Methods: The study was a prospective multicenter cross-sectional study. Primary endpoints were the Asthma Control Test™ (ACT) in the asthma part of the study and the COPD Assessment Test™ (CAT) for the COPD part., Results: A total of 1038 asthma patients and 846 COPD patients were included, of whom about 70 % participated in the corresponding DMP. The ACT total score was higher in asthma DMP+ patients than in DMP- patients (mean difference 0.86; 95 %CI:0.29 - 1.43;p = 0.003), but not clinically relevant. For COPD there was no clinically relevant difference in COPD disease impact (0.52; 95 %CI:-0.71 - 1.75;p = 0.405). Although DMP patients had to be enrolled in the respective DMP for at least one year, only 60 % of these patients had participated in a structured education. We did not observe a difference in disease control in DMP patients who respectively participated and did not participate in a structured education., Discussion: There was no clinically relevant difference in disease control between DMP+ and DMP- patients. The efficacy of DMPs has been demonstrated internationally in randomized controlled trials. Randomized controlled trials should be conducted in Germany for demonstrating efficacy of DMPs asthma and COPD., Registration: drks.de, DRKS00007664, Registration date: Jan 15, 2015., Competing Interests: Diese Studie wurde durch die Mundipharma GmbH finanziert. P. O. und B.L-B. sind Mitarbeiterinnen der Mundipharma GmbH. F.K. und A.Z. haben Beraterverträge mit der Mundipharma GmbH. A.Z. ist Mitglied der Schriftleitung der Dtsch Med Wochenschr., (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.